82 FR 23251 - Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention Federal Register Volume 82, Issue 97 (May 22, 2017)
Centers for Disease Control and Prevention
Federal Register Volume 82, Issue 97 (May 22, 2017)
| Page Range | 23251-23251 | |
| FR Document | 2017-10334 |
[Federal Register Volume 82, Number 97 (Monday, May 22, 2017)] [Notices] [Page 23251] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-10334] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review The meeting announced below concerns the Centers for Disease Control and Prevention (CDC) initial review of applications in response to Funding Opportunity Announcement (FOA) GH16-006, Conducting Public Health Research in Kenya; GH17-004, Conducting Public Health Research Activities in Egypt; GH17-005, Conducting Public Health Research in China. This publication corrects a notice that was published in the Federal Register on May 4, 2017, Volume 82, Number 85, pages 20894- 20895. The meeting announcement and matters for discussion should read as follows: The meeting announced below concerns the Centers for Disease Control and Prevention (CDC) initial review of applications in response to Funding Opportunity Announcement (FOA) GH17-005, Conducting Public Health Research in China. Time and Date: 9:00 a.m.-2:00 p.m., EDT, May 24, 2017 Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ``Conducting Public Health Research in China'', GH17-005. FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Scientific Review Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 1600 Clifton Road, NE., Mailstop D-69, Atlanta, Georgia 30033, Telephone: (404) 639-4796, [email protected]. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017-10334 Filed 5-19-17; 8:45 am] BILLING CODE 4163-18-P
![Federal Register / Vol. 82, No. 97 / Monday, May 22, 2017 / Notices 23251
and epidemiologic studies. announcement and matters for DATES: The meeting will be held on June
Subcommittee proposals on lead discussion should read as follows: 20, 2017, from 8 a.m. to 5 p.m.
prevention practices and national lead The meeting announced below Comments received on or before June 6,
poisoning prevention efforts will be concerns the Centers for Disease Control 2017, will be provided to the committee.
provided to the Board of Scientific and Prevention (CDC) initial review of Comments received after that date will
Counselors for deliberation and possible applications in response to Funding be taken into consideration by the
adoption as formal recommendations to Opportunity Announcement (FOA) Agency.
NCEH/ATSDR. GH17–005, Conducting Public Health
Matters for Discussion: Agenda items Research in China. ADDRESSES: FDA White Oak Campus,
will include the following: Lead Time and Date: 9:00 a.m.–2:00 p.m., 10903 New Hampshire Avenue,
Poisoning Prevention Program (status), EDT, May 24, 2017 Building. 31 Conference Center, the
Flint Registry (status), Revision of Blood Matters for Discussion: The meeting Great Room (Rm. 1503), Silver Spring,
Lead Level reference value (status), will include the initial review, MD 20993–0002. Answers to commonly
Discussion of legislative requirements of discussion, and evaluation of asked questions including information
a new Lead Exposure and Prevention applications received in response to regarding special accommodations due
Federal Advisory Committee, Federal ‘‘Conducting Public Health Research in to a disability, visitor parking, and
partnership efforts. China’’, GH17–005. transportation may be accessed at:
Agenda items are subject to change as FOR FURTHER INFORMATION CONTACT: http://www.fda.gov/Advisory
priorities dictate. Hylan Shoob, Scientific Review Officer, Committees/AboutAdvisoryCommittees/
Contact Person for More Information: Center for Global Health (CGH) Science ucm408555.htm.
Amanda Malasky, Coordinator, Lead Office, CGH, CDC, 1600 Clifton Road,
FDA is establishing a docket for
Poisoning Prevention Subcommittee, NE., Mailstop D–69, Atlanta, Georgia
public comment on this meeting. The
BSC, NCEH/ATSDR, 4770 Buford 30033, Telephone: (404) 639–4796,
docket number is FDA–2017–N–1988.
Highway, Mail Stop F–45, Chamblee, CGHERPO@CDC.GOV.
The Director, Management Analysis All submissions received must include
Georgia 30345; telephone 770/488–
and Services Office, has been delegated the Docket No. FDA–2017–N–1988 for
7699, Fax: 770/488–3377; Email:
the authority to sign Federal Register ‘‘Endocrinologic and Metabolic Drugs
AMalasky@cdc.gov.
The Director, Management Analysis notices pertaining to announcements of Advisory Committee; Notice of Meeting;
and Services Office has been delegated meetings and other committee Establishment of a Public Docket;
the authority to sign Federal Register management activities, for both the Request for Comments.’’ For detailed
notices pertaining to announcements of Centers for Disease Control and instructions on sending comments, see
meetings and other committee Prevention and the Agency for Toxic the ‘‘Public Participation’’ heading of
management activities, for both the Substances and Disease Registry. the SUPPLEMENTARY INFORMATION section
Centers for Disease Control and of this document. You may submit
Elaine L. Baker, comments as follows:
Prevention and the Agency for Toxic Director, Management Analysis and Services
Substances and Disease Registry. Office, Centers for Disease Control and Electronic Submissions
Elaine L. Baker, Prevention.
Submit electronic comments in the
Director, Management Analysis and Services [FR Doc. 2017–10334 Filed 5–19–17; 8:45 am]
following way:
Office, Centers for Disease Control and BILLING CODE 4163–18–P
Prevention. • Federal eRulemaking Portal:
[FR Doc. 2017–10333 Filed 5–19–17; 8:45 am] https://www.regulations.gov/. Follow
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND the instructions for submitting
HUMAN SERVICES comments. Comments submitted
electronically, including attachments, to
DEPARTMENT OF HEALTH AND Food and Drug Administration https://www.regulations.gov/ will be
HUMAN SERVICES [Docket No. FDA–2017–N–1988] posted to the docket unchanged.
Because your comment will be made
Centers for Disease Control and Endocrinologic and Metabolic Drugs public, you are solely responsible for
Prevention Advisory Committee; Notice of ensuring that your comment does not
Meeting; Establishment of a Public include any confidential information
Disease, Disability, and Injury Docket; Request for Comments that you or a third party may not wish
Prevention and Control Special to be posted, such as medical
Emphasis Panel (SEP): Initial Review AGENCY: Food and Drug Administration, information, your or anyone else’s
HHS. Social Security number, or confidential
The meeting announced below ACTION: Notice; establishment of a
concerns the Centers for Disease Control business information, such as a
public docket; request for comments. manufacturing process. Please note that
and Prevention (CDC) initial review of
applications in response to Funding SUMMARY: The Food and Drug if you include your name, contact
Opportunity Announcement (FOA) Administration (FDA or Agency) information, or other information that
GH16–006, Conducting Public Health announces a forthcoming public identifies you in the body of your
Research in Kenya; GH17–004, advisory committee meeting of the comments, that information will be
Conducting Public Health Research Endocrinologic and Metabolic Drugs posted on https://www.regulations.gov/.
mstockstill on DSK30JT082PROD with NOTICES
Activities in Egypt; GH17–005, Advisory Committee. The general • If you want to submit a comment
Conducting Public Health Research in function of the committee is to provide with confidential information that you
China. advice and recommendations to the do not wish to be made available to the
This publication corrects a notice that Agency on FDA’s regulatory issues. The public, submit the comment as a
was published in the Federal Register meeting will be open to the public. FDA written/paper submission and in the
on May 4, 2017, Volume 82, Number 85, is establishing a docket for public manner detailed (see ‘‘Written/Paper
pages 20894–20895. The meeting comment on this document. Submissions’’ and ‘‘Instructions’’).
VerDate Sep<11>2014 23:17 May 19, 2017 Jkt 241001 PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 E:\FR\FM\22MYN1.SGM 22MYN1](https://thefederalregister.org/doc/82_FR_23348/page/1.svg)
Document Created: 2018-11-08 08:50:16
Document Modified: 2018-11-08 08:50:16
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | 9:00 a.m.-2:00 p.m., EDT, May 24, 2017 | |
| Contact | Hylan Shoob, Scientific Review Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 1600 Clifton Road, NE., Mailstop D-69, Atlanta, Georgia 30033, Telephone: (404) 639-4796, [email protected] | |
| FR Citation | 82 FR 23251 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR